X Pharma Series Review

: Eliminates the high costs and logistical hurdles of maintaining a physical animal house, making quality education more affordable for institutions.

Global health is desperate for narrow-spectrum agents that spare the gut microbiome. The Series allows researchers to swap a single aryl ring to shift activity from Gram-positive to Gram-negative bacteria. X-88, currently in Phase II, is a first-in-class LpxC inhibitor that targets Pseudomonas aeruginosa without affecting Staphylococcus or gut commensals. x pharma series

“Exactly. Because they show that Patient 212—male, 72, no prior psychiatric history—now believes his wife of fifty years has been replaced by an ‘imposter who smells like ozone.’ He’s stopped eating. He thinks she’s poisoning him.” : Eliminates the high costs and logistical hurdles

serves as a roadmap for navigating this new terrain, ensuring that as we move toward a future of "super-medicine," we don't lose our humanity in the process. X-88, currently in Phase II, is a first-in-class

is a venture capital firm involved in high-level pharmaceutical and health-tech funding. Recent Activity: In March 2026, it led a $300 million funding round for

“They’re waking up, Lena. The ones who were here before us. And they’re hungry.”